Shiran Sun1, Xiaodong Huang2, Li Gao3, Ye Zhang4, Jingwei Luo5, Shiping Zhang6, Kai Wang7, Yuan Qu8, Runye Wu9, Qingfeng Liu10, Jianping Xiao11, Guozhen Xu12, Junlin Yi13. 1. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: cindy899@126.com. 2. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: hxd010@hotmail.com. 3. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: li_gao2008@outlook.com. 4. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: drzye@163.com. 5. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: nqluo202@163.com. 6. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: zhshp1@hotmail.com. 7. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: kaiwang2001@vip.sina.com. 8. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: qu_yuan01@163.com. 9. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: wurunye@aliyun.com. 10. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: qingfeng1910@163.com. 11. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: jpxiao8@163.com. 12. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: guozhenxu@vip.sina.com. 13. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: yijunlin1969@163.com.
Abstract
OBJECTIVES: This study aimed to evaluate the clinical features, treatment outcomes and prognostic factors of mucosal melanoma of the head and neck (MMHN) in patients who were treated at our institution. MATERIALS AND METHODS: Between Jan. 1981 and Oct. 2015, 161 patients with non-metastatic MMHN were treated at our institution. The patients' clinical characteristics, treatment modalities, outcomes, prognostic factors, and failure patterns were retrospectively analysed. RESULTS: With a median follow-up time of 74months, the 5-year overall survival rate (OS), local control rate (LC), distant metastasis-free survival (DMFS) were 44.4%, 59.4%, and 49.3%, respectively. Regarding the different treatment modalities, the 5-year OS was 50.0% in the surgery group and 43.1% in the surgery combined with radiotherapy group, while, the 5-year LC rate was 42.5% in the surgery group and 75.3% in the surgery combined with radiotherapy (p<0.001). According to the AJCC 7th edition staging system for MMHN, the 5-year OS for patients with stage III, stage IVA, and stage IVB MMHN were 65.2%, 33.1% and 14.3%, respectively (p<0.001). In the multivariate analysis, the T stage, neck lymph node involvement, and surgical margins were independent prognostic factors for OS; surgical margins and adjuvant radiotherapy were independent prognostic factors for LC. CONCLUSION: The addition of radiotherapy improves the local control rate of MMHN. T stage, neck lymph node status, and surgical margins are independent prognostic factors for the OS in patients with MMHN. The AJCC 7th edition staging system for MMHN appears to effectively stage this disease.
OBJECTIVES: This study aimed to evaluate the clinical features, treatment outcomes and prognostic factors of mucosal melanoma of the head and neck (MMHN) in patients who were treated at our institution. MATERIALS AND METHODS: Between Jan. 1981 and Oct. 2015, 161 patients with non-metastatic MMHN were treated at our institution. The patients' clinical characteristics, treatment modalities, outcomes, prognostic factors, and failure patterns were retrospectively analysed. RESULTS: With a median follow-up time of 74months, the 5-year overall survival rate (OS), local control rate (LC), distant metastasis-free survival (DMFS) were 44.4%, 59.4%, and 49.3%, respectively. Regarding the different treatment modalities, the 5-year OS was 50.0% in the surgery group and 43.1% in the surgery combined with radiotherapy group, while, the 5-year LC rate was 42.5% in the surgery group and 75.3% in the surgery combined with radiotherapy (p<0.001). According to the AJCC 7th edition staging system for MMHN, the 5-year OS for patients with stage III, stage IVA, and stage IVB MMHN were 65.2%, 33.1% and 14.3%, respectively (p<0.001). In the multivariate analysis, the T stage, neck lymph node involvement, and surgical margins were independent prognostic factors for OS; surgical margins and adjuvant radiotherapy were independent prognostic factors for LC. CONCLUSION: The addition of radiotherapy improves the local control rate of MMHN. T stage, neck lymph node status, and surgical margins are independent prognostic factors for the OS in patients with MMHN. The AJCC 7th edition staging system for MMHN appears to effectively stage this disease.
Authors: Cristina Valero; Dauren Adilbay; Conall W R Fitzgerald; Avery Yuan; Ximena Mimica; Piyush Gupta; Richard J Wong; Jatin P Shah; Snehal G Patel; Marc A Cohen; Ian Ganly Journal: Oral Oncol Date: 2021-10-21 Impact factor: 5.337
Authors: Stephanie Flukes; Shivangi Lohia; Christopher A Barker; Jennifer R Cracchiolo; Ian Ganly; Snehal G Patel; Benjamin R Roman; Jatin P Shah; Alexander N Shoushtari; Viviane Tabar; Akash Shah; Marc A Cohen Journal: Head Neck Date: 2020-08-01 Impact factor: 3.147
Authors: Ji-Jin Yao; Fan Zhang; Guang-Shun Zhang; Xiao-Wu Deng; Wang-Jian Zhang; Wayne R Lawrence; Lu Zou; Xiao-Shi Zhang; Li-Xia Lu Journal: Cancer Manag Res Date: 2018-12-14 Impact factor: 3.989
Authors: Qing-Qing Xu; Qing-Jie Li; Liu Chen; Xin-Yi Su; Jing-Xia Song; Juan Du; Lei Chen; Li-Xia Lu Journal: Cancer Cell Int Date: 2021-04-17 Impact factor: 5.722